[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 172, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sven Ante Lundberg M.D.", "age": 60, "title": "CEO, President & Executive Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1114527, "exercisedValue": 0, "unexercisedValue": 10252539}, {"maxAge": 1, "name": "Mr. Gregory D. Perry", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 419102, "exercisedValue": 0, "unexercisedValue": 801494}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 45, "title": "EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 781842, "exercisedValue": 565022, "unexercisedValue": 1331558}, {"maxAge": 1, "name": "Ms. Anne  Van der Touw Noordzij", "title": "Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 55.69, "open": 55.87, "dayLow": 54.88, "dayHigh": 56.395, "regularMarketPreviousClose": 55.69, "regularMarketOpen": 55.87, "regularMarketDayLow": 54.88, "regularMarketDayHigh": 56.395, "beta": 1.123, "forwardPE": -17.228395, "volume": 429957, "regularMarketVolume": 429957, "averageVolume": 1047042, "averageVolume10days": 873230, "averageDailyVolume10Day": 873230, "bid": 55.73, "ask": 55.86, "bidSize": 200, "askSize": 100, "marketCap": 3760593408, "fiftyTwoWeekLow": 19.805, "fiftyTwoWeekHigh": 61.61, "priceToSalesTrailing12Months": 98.093056, "fiftyDayAverage": 51.5636, "twoHundredDayAverage": 37.5904, "currency": "USD", "enterpriseValue": 2949970176, "floatShares": 47291015, "sharesOutstanding": 67370000, "sharesShort": 6844367, "sharesShortPriorMonth": 3482923, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.1016, "heldPercentInsiders": 0.06511, "heldPercentInstitutions": 0.80133003, "shortRatio": 4.46, "shortPercentOfFloat": 0.1022, "impliedSharesOutstanding": 67370000, "bookValue": 5.954, "priceToBook": 9.37521, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -149654000, "trailingEps": -2.73, "forwardEps": -3.24, "pegRatio": 2.22, "enterpriseToRevenue": 76.948, "enterpriseToEbitda": -17.983, "52WeekChange": 1.1321619, "SandP52WeekChange": 0.24919295, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "42321671-9233-3f73-a2ee-487472589127", "messageBoardId": "finmb_24929296", "gmtOffSetMilliseconds": -14400000, "currentPrice": 55.82, "targetHighPrice": 100.0, "targetLowPrice": 67.0, "targetMeanPrice": 87.42, "targetMedianPrice": 89.5, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 337496000, "totalCashPerShare": 5.751, "ebitda": -164044992, "totalDebt": 11527000, "quickRatio": 5.07, "currentRatio": 5.227, "totalRevenue": 38337000, "debtToEquity": 3.299, "revenuePerShare": 0.703, "returnOnAssets": -0.24892999, "returnOnEquity": -0.52791, "freeCashflow": -129249504, "operatingCashflow": -149852000, "revenueGrowth": -0.416, "grossMargins": -2.766, "operatingMargins": -5.9334497, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-11"}]